Eli Lilly announced plans to acquire three biotechnology companies—Curevo, LimmaTech Biologics, and Vaccine Company—to strengthen its infectious disease and vaccine development portfolio. The acquisitions focus on preventing viral and bacterial infections linked to long-term health complications such as neurological disease, cancer, infertility, and antimicrobial resistance. Key programs include an improved shingles vaccine with fewer side effects, vaccines targeting difficult-to-treat bacterial pathogens like Staphylococcus aureus and gonorrhea, and a next-generation Epstein-Barr virus vaccine platform aimed at preventing diseases associated with EBV, including multiple sclerosis and certain cancers. Lilly said the strategy reflects a broader push toward prevention-focused approaches as infectious diseases continue to pose major global health risks. Read the full story at Lilly
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.